Ed Esplin, SVP of Medical Affairs at Biocartis, shared on LinkedIn:
“Underutilization of germline genetictesting
90% of eligible patients with urologic cancer do not receive germline testing
Of >125K eligible patients with cancer these had germlinetesting:
- kidneycancer 9%
- adrenalcancer 9%
- UTUC 16%
- bladdercancer 8%
- prostatecancer 10%
100% of the above patients with urologiccancer met guideline eligibility for genetic testing
‘With constantly changing guidelines, varying criteria across guidelines and less sensitive guidelines, the authors propose the need for…universally established guidelines…that effectively identifies most patients with genetic conditions.’
(i.e. Universal germlinetesting for all patients with urologiccancer per Neal Shore et al.”
Title: Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now
Authors: Neal Shore, Sarah M. Nielsen, Edward D. Esplin, Emmanuel S. Antonarakis, Pedro C. Barata, Tomasz M. Beer, Himisha Beltran, Alan Bryce, Michael S. Cookson, E. David Crawford, Tanya B. Dorff, Daniel J. George, Elisabeth I. Heath, Brian T. Helfand, Maha Hussain, Rana R. Mckay, Alicia K. Morgans, Michael J. Morris, Channing J. Paller, Ashley E. Ross, Oliver Sartor, John Shen, Paul Sieber, Matthew R. Smith, David R. Wise, Andrew J. Armstrong
Read the Full Article.
